Eli Lilly shares weekly forecast: Strong demand for obesity drugs supports sustained gains

Traders Union
All News
Stocks
Eli lilly rises 2.30% this week

Highlights

Shares of Eli Lilly gained 2.3% in the past week, closing at $1,286 near the top of their recent range.
The stock maintains a strong bullish structure, holding well above key short-term moving averages with clear upward momentum.
Eli Lilly shares are expected to fluctuate between $1,237 and $1,334 in the coming week, with momentum indicators showing an overbought condition and a high probability of further gains.

All-time high reached as EU regulatory progress and partnerships accelerate growth outlook

Eli Lilly recently reached a new all-time high in market capitalization, surpassing Berkshire Hathaway, driven by robust demand for its weight-management and diabetes treatments, according to Yahoo Finance. The company saw further support after the European Medicines Agency recommended approval for its oral obesity drug, Foundayo, bringing it near final approval in the EU (source: Pluang). Additionally, LLY entered a $1.1 billion partnership with Metis TechBio to advance AI-driven nanoparticle drug discovery and is set to present new late-stage oncology data at the upcoming 2026 ESMO Congress in Madrid (sources: FierceBiotech, stocktitan.net). The recent launch of the LillyDirect telehealth platform may also impact direct consumer access to its top therapies (source: PharmExec).

Momentum remains stretched as overbought indicators highlight upside risk

On the daily chart, the technical setup shows strong upward momentum, with a sharp move higher without a sustained trend and volatility at 8.98%. The RSI stands at 70.35 in the overbought zone, and Bull/Bear Power is also overbought, indicating that buyers have dominated the recent action. Immediate support is seen at $1,221 from the Ichimoku Kijun, while resistance sits at the recent high of $1,311. Momentum appears stretched here, but the constructive structure keeps the overall bias tilted upward for now.

Further consolidation expected as breakout potential hinges on resistance

Over the coming trading week, Eli Lilly is expected to range between $1,237 and $1,334. There is a very high probability of an increase and a very low probability of a decrease in price. The base case is for continued consolidation within this band. A breakout above $1,311 could see further upside toward the upper end of the forecast, while a drop below support at $1,221 would weaken the constructive setup and open scope for a pullback.

Viktoras Karapetjanc, analyst at Traders Union, sees sustained upside in shares of Eli Lilly following a strong 2% gain this week to $1,286. He notes that bullish sentiment is underpinned by exceptional demand for the company’s weight-management and diabetes drugs, a strategic $1.1 billion partnership for AI-driven R&D, and positive regulatory progress in the EU. Daily technicals confirm strong momentum, with the RSI at 70.35 and both support at $1,221 and resistance at $1,311 framing the near-term setup. Momentum looks stretched, but the upward structure remains intact and recent news flow supports further upside potential. "With confidence high and fundamentals solid, I expect Eli Lilly to consolidate with an upward bias and see further growth possible above $1,311 in the coming week."

Earlier, analysts noted that Eli Lilly's strong technical momentum and ongoing pipeline and partnership developments positioned the stock for potential gains within its trading range. The current article strengthens that perspective by highlighting persistent upward momentum supported by new regulatory milestones, with the key scenario now hinging on whether LLY can break above $1,311 to unlock further upside in the near term.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.